gavreto

Generic: pralsetinib

gavreto: developed by 1 company · 1 FDA decision. Updated within the last hour.

Development Pipeline (1)

CompanyPhase
RIGEL PHARMACEUTICALS INC (RIGL)Approved

FDA Decisions

Approval1 INDICATIONS AND USAGE GAVRETO is a kinase inhibitor indicated for treatment of: Adult patients with metastatic rearranged during transfection (RET ) fusion-positive non-small cell lung cancer as detected by an FDA approved test (NSCLC). ( 1.1 ) Adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). This indication is appro(RIGL)

Frequently asked questions

Who is developing gavreto?

gavreto is being developed by RIGEL PHARMACEUTICALS INC.

What is gavreto's latest FDA decision?

The most recent tracked FDA decision for gavreto is Approval for 1 INDICATIONS AND USAGE GAVRETO is a kinase inhibitor indicated for treatment of: Adult patients with metastatic rearranged during transfection (RET ) fusion-positive non-small cell lung cancer as detected by an FDA approved test (NSCLC). ( 1.1 ) Adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). This indication is appro, dated September 4, 2020.

Get deeper analysis on gavreto

Full trial data, mechanism of action, competitive landscape, and AI-powered insights.

Start Free Analysis
    gavreto — Drug Pipeline, Trials & FDA Status | BioSniper